CRVO

CervoMed, Inc.'s stock has experienced significant volatility, declining by 62.71% from May 5, 2025, to May 1, 2026, and trading between $3.51 and $13.13 over the past 52 weeks. Positive clinical data and regulatory alignment for neflamapimod in DLB have created upward pressure, while missed earnings, reporting an EPS of -$0.88, missing the consensus estimate of -$0.79, and quarterly revenue of $0.01 million also falling below analysts' expectations of $0.84 million, and cash runway concerns have negatively impacted the stock. Recent insider buying activity has also been noted.